Biomarkers /
NFKB2
Overview
Nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (p49/p100) (NFKB2) is a gene that encodes a protein that functions as a subunit of the transcription factor complex nuclear factor-kappa-B. The protein activates genes that participate in inflammation and immunity. Fusions, missense mutations, nonsense mutations, silent mutations, frameshift deletions, and in-frame deletions are observed in cancers such as bone cancer, endometrial cancer, and skin cancer.
NFKB2 is altered in 1.32% of all cancers with cervical squamous cell carcinoma, endometrial endometrioid adenocarcinoma, high grade ovarian serous adenocarcinoma, ovarian epithelial tumor, and anaplastic astrocytoma having the greatest prevalence of alterations [3].
The most common alterations in NFKB2 are NFKB2 Mutation (1.25%), NFKB2 P430S (0.36%), NFKB2 A572T (0.28%), NFKB2 A420T (0.22%), and NFKB2 A675T (0.39%) [3].
Clinical Trials
Significance of NFKB2 in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.